Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Liver Diseases

  Free Subscription


09.05.2022

2 AJR Am J Roentgenol
2 Am J Gastroenterol
1 Am J Pathol
3 Anticancer Res
1 Biochem Biophys Res Commun
1 BMC Cancer
1 BMC Gastroenterol
1 Br J Surg
1 Endoscopy
5 Gastroenterology
1 Gut
16 Hepatology
4 Indian J Gastroenterol
1 J Gastroenterol Hepatol
3 J Hepatol
2 Oncogene
8 PLoS One
1 Proc Natl Acad Sci U S A
3 Semin Liver Dis


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. LUNA A
    Editorial Comment: Integrated Diagnosis of Hepatocellular Carcinoma-An Opportunity for Abdominal Radiologists.
    AJR Am J Roentgenol. 2022 May 4:12. doi: 10.2214/AJR.22.27611.
    PubMed        

  2. CANNELLA R, Lewis S, da Fonseca L, Ronot M, et al
    Immunotherapy-Based Treatments of Hepatocellular Carcinoma: AJR Expert Panel Narrative Review.
    AJR Am J Roentgenol. 2022 May 4. doi: 10.2214/AJR.22.27633.
    PubMed         Abstract available


    Am J Gastroenterol

  3. CROCOMBE D, Freemantle N, O'Brien A
    Additional Analyses for the Published Primary Norfloxacin Prophylaxis for APASL-Defined Acute-on-Chronic Liver Failure.
    Am J Gastroenterol. 2022;117:814-815.
    PubMed        

  4. MIR BA, Majeed T, Chauhan A
    A New Window to Favorable Outcome in Acute-on-Chronic Liver Failure.
    Am J Gastroenterol. 2022;117:815.
    PubMed        


    Am J Pathol

  5. HARDESTY J, Day L, Warner J, Warner D, et al
    Hepatic protein and phosphoprotein signatures of alcohol-associated cirrhosis and hepatitis.
    Am J Pathol. 2022 Apr 28. pii: S0002-9440(22)00121.
    PubMed         Abstract available


    Anticancer Res

  6. HSIEH CH, Yeh CT, Huang YH, Lai MW, et al
    Circulating Tumor Cells Derived from Advanced Hepatocellular Carcinoma Rapidly Develop Resistance to Cytotoxic Chemotherapy.
    Anticancer Res. 2022;42:2479-2486.
    PubMed         Abstract available

  7. KUMAMOTO T, Matsuyama R, Takeda K, Sawada YU, et al
    Surgical Indications for Huge Hepatocellular Carcinoma.
    Anticancer Res. 2022;42:2573-2581.
    PubMed         Abstract available

  8. YANG CJ, Wu MH, Tsai JJ, Hsu FT, et al
    Inactivation of AKT/ERK Signaling and Induction of Apoptosis Are Associated With Amentoflavone Sensitization of Hepatocellular Carcinoma to Lenvatinib.
    Anticancer Res. 2022;42:2495-2505.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  9. LIAO C, Zhang L, Jiang R, Xu J, et al
    Inhibition of NAD kinase elevates the hepatic NAD(+) pool and alleviates acetaminophen-induced acute liver injury in mice.
    Biochem Biophys Res Commun. 2022;612:70-76.
    PubMed         Abstract available


    BMC Cancer

  10. KAZAMA H, Kawaguchi O, Seto T, Suzuki K, et al
    Comprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer.
    BMC Cancer. 2022;22:470.
    PubMed         Abstract available


    BMC Gastroenterol

  11. GUO H, Zhang M, Zhang N, Yin X, et al
    Number of endoscopic sessions to eradicate varices identifies high risk of rebleeding in cirrhotic patients.
    BMC Gastroenterol. 2022;22:213.
    PubMed         Abstract available


    Br J Surg

  12. WEI T, Zhang XF, He J, Popescu I, et al
    Prognostic impact of perineural invasion in intrahepatic cholangiocarcinoma: multicentre study.
    Br J Surg. 2022 May 3. pii: 6577149. doi: 10.1093.
    PubMed         Abstract available


    Endoscopy

  13. HAN C, Ling X, Liu J, Ding Z, et al
    A new therapy for refractory gastric cancer bleeding: endoscopic ultrasound-guided lauromacrogol injection.
    Endoscopy. 2021 Apr 16. doi: 10.1055/a-1398-5196.
    PubMed        


    Gastroenterology

  14. COPPS KD, Tao R
    A role for hepatic insulin signaling in alpha1-antitrypsin deficiency.
    Gastroenterology. 2022 Apr 29. pii: S0016-5085(22)00457.
    PubMed        

  15. CACCIOLA I
    Effects of PPIs in cirrhotic patients: What do we really know?
    Gastroenterology. 2022 Apr 29. pii: S0016-5085(22)00452.
    PubMed        

  16. QIAN T, Fujiwara N, Koneru B, Ono A, et al
    Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development.
    Gastroenterology. 2022;162:1210-1225.
    PubMed         Abstract available

  17. XU P, Xi Y, Wang P, Luka Z, et al
    Inhibition of p53 Sulfoconjugation Prevents Oxidative Hepatotoxicity and Acute Liver Failure.
    Gastroenterology. 2022;162:1226-1241.
    PubMed         Abstract available

  18. YANG Y, Ju C
    Sulfation in Acetaminophen-Induced Liver Injury: Friend or Foe?
    Gastroenterology. 2022;162:1035-1037.
    PubMed        


    Gut

  19. RIVOLTINI L, Bhoori S, Camisaschi C, Bergamaschi L, et al
    Y(90)-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers.
    Gut. 2022 May 4. pii: gutjnl-2021-326869. doi: 10.1136/gutjnl-2021-326869.
    PubMed        


    Hepatology

  20. SANGRO B, Argemi J
    Immunotherapy in hepatocellular carcinoma - No rush despite the hype.
    Hepatology. 2022 May 1. doi: 10.1002/hep.32550.
    PubMed        

  21. QIN Y, Li A, Liu B, Gao M, et al
    Comment on "Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD".
    Hepatology. 2022 May 1. doi: 10.1002/hep.32551.
    PubMed        

  22. LIU JJ, Xin B, Du L, Chen L, et al
    Pharmaceutical Shp2 inhibition suppresses primary and metastasized liver tumors by provoking hepatic innate immunity.
    Hepatology. 2022 May 3. doi: 10.1002/hep.32555.
    PubMed         Abstract available

  23. GULATI P, Taneja S, Duseja A, Singh V, et al
    Letter to Editor-Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study- Should we extend the boundaries?
    Hepatology. 2022 May 3. doi: 10.1002/hep.32554.
    PubMed        

  24. ANDERSEN JB
    Stromal yin-yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinoma.
    Hepatology. 2022 May 3. doi: 10.1002/hep.32558.
    PubMed        

  25. LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
    Primary Biliary Cholangitis: 2021 Practice Guidance Update from the American Association for the Study of Liver Diseases.
    Hepatology. 2021 Aug 24. doi: 10.1002/hep.32117.
    PubMed         Abstract available

  26. SUBRAMANIAN P, Gargani S, Palladini A, Chatzimike M, et al
    The RNA binding protein human antigen R is a gatekeeper of liver homeostasis.
    Hepatology. 2022;75:881-897.
    PubMed         Abstract available

  27. ZHOU HZ, Li F, Cheng ST, Xu Y, et al
    DDX17-regulated alternative splicing that produced an oncogenic isoform of PXN-AS1 to promote HCC metastasis.
    Hepatology. 2022;75:847-865.
    PubMed         Abstract available

  28. KWAN SY, Jiao J, Joon A, Wei P, et al
    Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease.
    Hepatology. 2022;75:955-967.
    PubMed         Abstract available

  29. NEIL DAH, Minervini M, Smith ML, Hubscher SG, et al
    Banff consensus recommendations for steatosis assessment in donor livers.
    Hepatology. 2022;75:1014-1025.
    PubMed         Abstract available

  30. WU N, Carpino G, Ceci L, Baiocchi L, et al
    MT1 but not MT2 melatonin receptor knockout decreases biliary damage and liver fibrosis during cholestatic liver injury.
    Hepatology. 2021 Nov 7. doi: 10.1002/hep.32233.
    PubMed         Abstract available

  31. PAILHORIES H, Boursier J, Diehl AM
    Determinants of the severity of fatty liver diseases: Need all the pieces to solve the puzzle.
    Hepatology. 2022;75:782-784.
    PubMed        

  32. COLASANTI T, Di Giamberardino A, Grimaldi A, Cardinale V, et al
    Letter to the editor: Serum thrombospondin-2 as biomarker in liver diseases, a look beyond NASH.
    Hepatology. 2022;75:1056-1057.
    PubMed        

  33. JAIN A, Sharma BC
    Reply.
    Hepatology. 2022;75:1066-1067.
    PubMed        

  34. WANG S, Whitlock R, Lai JC, Taneja S, et al
    Reply.
    Hepatology. 2022;75:1068-1069.
    PubMed        

  35. SINGH SA, Madan K, Gupta S, Indrayan A, et al
    Letter to the editor: Relevance of population-based cutoffs to define frailty in clinical studies.
    Hepatology. 2022;75:1067-1068.
    PubMed        


    Indian J Gastroenterol

  36. JHA P, Jha AK, Dayal VM, Jha SK, et al
    Baseline serum cystatin C as a marker of acute kidney injury in patients with acute-on-chronic liver failure.
    Indian J Gastroenterol. 2021;40:563-571.
    PubMed         Abstract available

  37. SINGH S, Goel S, Aggarwal A, Iqbal A, et al
    Combination of portal vein embolization and neoadjuvant chemotherapy for locally advanced gallbladder cancer requiring extended hepatectomy - A novel approach.
    Indian J Gastroenterol. 2021;40:580-589.
    PubMed         Abstract available

  38. YAMASANDHI PG, Dharmalingam M, Balekuduru A
    Fetuin-A in newly detected type 2 diabetes mellitus as a marker of non-alcoholic fatty liver disease.
    Indian J Gastroenterol. 2021;40:556-562.
    PubMed         Abstract available

  39. JAGTAP N, Kalapala R, Katakwar A, Sharma M, et al
    Endoscopic sleeve gastroplasty - minimally invasive treatment for non-alcoholic fatty liver disease and obesity.
    Indian J Gastroenterol. 2021;40:572-579.
    PubMed         Abstract available


    J Gastroenterol Hepatol

  40. WANG X, Gao X, Wu R, Chi X, et al
    Serum qAnti-HBc combined with ALT and HBsAg predicts significant hepatic inflammation in HBeAg-positive immune active patients.
    J Gastroenterol Hepatol. 2022 May 4. doi: 10.1111/jgh.15881.
    PubMed         Abstract available


    J Hepatol

  41. LIU C, Zha Z, Zhou C, Chen Y, et al
    Erratum to 'Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma' [J Hepatol 2021 (907-918)].
    J Hepatol. 2022 Apr 27. pii: S0168-8278(22)00240.
    PubMed        

  42. FERNANDEZ J, Prado V, Valdivieso M, Trebicka J, et al
    Response to: Association of rectal colonization by mdros with new infection in cirrhosis.
    J Hepatol. 2022 Apr 30. pii: S0168-8278(22)00257.
    PubMed        

  43. TANTAI X, Yeo YH, Wang J, Ji F, et al
    Reply to: "Evaluating sarcopenia in cirrhosis patients: the role of muscle function".
    J Hepatol. 2022 Apr 30. pii: S0168-8278(22)00259.
    PubMed        


    Oncogene

  44. LI B, Kang H, Xiao Y, Du Y, et al
    LncRNA GAL promotes colorectal cancer liver metastasis through stabilizing GLUT1.
    Oncogene. 2022 Feb 11. pii: 10.1038/s41388-022-02230.
    PubMed         Abstract available

  45. LI K, Niu Y, Yuan Y, Qiu J, et al
    Insufficient ablation induces E3-ligase Nedd4 to promote hepatocellular carcinoma progression by tuning TGF-beta signaling.
    Oncogene. 2022 Apr 30. pii: 10.1038/s41388-022-02334.
    PubMed         Abstract available


    PLoS One

  46. BAEK M, Chai JC, Choi HI, Yoo E, et al
    Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cells.
    PLoS One. 2022;17:e0266966.
    PubMed         Abstract available

  47. GOLD LC, Macpherson I, Nobes JH, Dow E, et al
    Thrombocytosis and abnormal liver enzymes: A trigger for investigation of underlying malignancy.
    PLoS One. 2022;17:e0267124.
    PubMed         Abstract available

  48. HU S, Zhang J, Guo G, Zhang L, et al
    Comprehensive analysis of GSEC/miR-101-3p/SNX16/PAPOLG axis in hepatocellular carcinoma.
    PLoS One. 2022;17:e0267117.
    PubMed         Abstract available

  49. MEZO M, Gonzalez-Warleta M, Castro-Hermida JA, Martinez-Sernandez V, et al
    Field evaluation of the enhanced MM3-COPRO ELISA test for the diagnosis of Fasciola hepatica infection in sheep.
    PLoS One. 2022;17:e0265569.
    PubMed         Abstract available

  50. HAMADA S, Takata T, Yamada K, Yamamoto M, et al
    Steatosis is involved in the progression of kidney disease in a high-fat-diet-induced non-alcoholic steatohepatitis mouse model.
    PLoS One. 2022;17:e0265461.
    PubMed         Abstract available

  51. PENG CH, Ker YB, Li HH, Tsou SH, et al
    Abelmoschus esculentus subfractions ameliorate hepatic lipogenesis and lipid uptake via regulating dipeptidyl peptidase-4-With improving insulin resistance.
    PLoS One. 2022;17:e0265444.
    PubMed         Abstract available

  52. KANEKO S, Kurosaki M, Tsuchiya K, Yasui Y, et al
    Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma.
    PLoS One. 2022;17:e0265235.
    PubMed         Abstract available

  53. GRASS JK, Kusters N, Kemper M, Tintrup J, et al
    Risk stratification of cirrhotic patients undergoing esophagectomy for esophageal cancer: A single-centre experience.
    PLoS One. 2022;17:e0265093.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  54. CHENG MT, Chen Y, Chen ZP, Liu X, et al
    Structural insights into the activation of autoinhibited human lipid flippase ATP8B1 upon substrate binding.
    Proc Natl Acad Sci U S A. 2022;119:e2118656119.
    PubMed         Abstract available


    Semin Liver Dis

  55. PANDAY R, Monckton CP, Khetani SR
    The Role of Liver Zonation in Physiology, Regeneration, and Disease.
    Semin Liver Dis. 2022;42:1-16.
    PubMed         Abstract available

  56. CADAMURO M, Lasagni A, Sarcognato S, Guido M, et al
    The Neglected Role of Bile Duct Epithelial Cells in NASH.
    Semin Liver Dis. 2022;42:34-47.
    PubMed         Abstract available

  57. TERZI E, Ayuso C, Piscaglia F, Bruix J, et al
    Liver Imaging Reporting and Data System: Review of Pros and Cons.
    Semin Liver Dis. 2022;42:104-111.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: